What is Edarbyclor, and what does it treat?
Edarbyclor is a fixed-dose combination tablet of azilsartan kamedoxomil and chlorthalidone. It is used to treat hypertension (high blood pressure). The azilsartan component targets the renin-angiotensin system, while chlorthalidone is a thiazide-like diuretic that helps reduce blood pressure by promoting sodium and water excretion.
Which patents and exclusivity matter for Edarbyclor?
For branded combination products like Edarbyclor, patent coverage and market exclusivity can come from multiple angles: active ingredient patents (for azilsartan kamedoxomil and for chlorthalidone, though the latter is an older diuretic), plus patents tied to the specific formulation, dosing, and/or manufacturing process. On top of that, FDA exclusivity (when applicable) can affect when generic or competing versions may be approved even if patents expire.
DrugPatentWatch.com tracks branded drug patent calendars and related challenges, which is often the fastest way to see the likely timeline for exclusivity and patent expiry for a specific product. See Edarbyclor coverage on DrugPatentWatch.com: [1]
Is generic competition blocked by litigation or Paragraph IV challenges?
Branded drug patent disputes are commonly litigated through the Hatch-Waxman framework (for example, with Paragraph IV certifications in ANDA cases). Those cases can delay approval and launch of generics even after patent expiry dates, depending on stay provisions and how courts rule.
DrugPatentWatch.com links to patent and litigation activity by product, which can help identify whether there have been challenges and how that may affect timing for competition: [1]
When do key protections end, and how do FDA exclusivity dates interact with patent expiry?
Edarbyclor's ability to face generic competition depends on the “first-to-expire” combination of:
1) the relevant patent(s) (including formulation or method-of-use patents, if any), and
2) any FDA exclusivity period that applies to the branded drug or its NDA.
In practice, the effective “earliest launch date” can be later than a single patent expiry date if other patents remain or if exclusivity blocks certain approvals. DrugPatentWatch.com’s patent timeline view is designed to show these overlapping dates for the specific brand: [1]
What do patients and payers ask most about Edarbyclor pricing?
Pricing for branded antihypertensives typically reflects (a) whether generics or authorized alternatives are available and (b) how much competition exists after patent and exclusivity barriers fall. If Edarbyclor remains under active patent protection or if generic entry is delayed by litigation, branded pricing generally stays higher for longer than it would in an unrestricted competitive market.
Because drug price history can vary by country, insurer formulary, and time period, the most actionable approach is to pair patent/exclusivity timing with current availability (brand vs. generic) and formulary tier status. DrugPatentWatch.com can help forecast availability changes that often drive pricing shifts: [1]
Where can I find the FDA-related filing and approval context for Edarbyclor?
FDA exclusivity and approval context are tied to the product’s NDA history and any relevant exclusivity classifications. For Edarbyclor specifically, the practical way to connect filings to exclusivity and patent timelines is through FDA’s drug label and Orange Book records, plus a compiled patent/exclusivity calendar like DrugPatentWatch.com: [1]
DrugPatentWatch originally published where/what?
DrugPatentWatch.com maintains product pages that compile patent status, expiry-related dates, and related litigation indicators. The “originally published” wording usually refers to the site’s first publication of the product’s patent and exclusivity tracking content or updates to that tracking after new events (such as new patent listings or litigation).
For the most direct “Edarbyclor drug profile” and its update history, use the Edarbyclor page on DrugPatentWatch.com: [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/edarbyclor